October 2, 1998
AMERIPATH ACQUIRES TWO PATHOLOGY PRACTICES

Riviera Beach, FL, October 2, 1998 - AmeriPath, Inc. (Nasdaq: PATH), a physician practice management company focused on anatomic pathology services, announced today that it has completed the acquisitions of two anatomic pathology practices located in Youngstown, Ohio and Denison, Texas. These acquisitions had a combined annual net revenue of approximately $8.5 million. Terms of the transactions were not disclosed.

Consultant Pathology Associates, Inc. is a hospital based pathology practice located in Youngstown, Ohio and employs 15 board-certified pathologists with subspecialties in Dermatopathology, Hematopathology, Chemical Pathology, Cytopathology and Blood Banking. The practice provides inpatient and outpatient anatomic pathology services to St. Elizabeth Health Center, St. Joseph Health Center and Northside Medical Center. Northside Medical Center is a major teaching hospital affiliated with Northeastern Ohio Universities College of Medicine.

Texoma Pathology Associates, P.A. is an outpatient pathology practice that has built a solid reputation in the Dallas metropolitan market for over 20 years. The practice employs two board-certified pathologists and provides inpatient and outpatient anatomic pathology services to nine hospitals and a number of outpatient surgery centers.

James C. New, President and CEO of AmeriPath said, "We're especially pleased to have these groups join the AmeriPath family. Their proximity to other existing AmeriPath practices will enhance our overall physician coverage and will give us the ability to work more effectively with referring hospital organizations, physicians and managed care groups."

AmeriPath, Inc. is the nation's leading physician practice management company focused on providing anatomic pathology services to physicians, hospitals, national clinical laboratories and managed care organizations. The Company presently operates in ten states, employs 213 pathologists who provide medical services through outpatient pathology laboratories, hospital inpatient laboratories and outpatient surgery centers.

.....................................................................................................................

This release contains certain forward-looking statements regarding AmeriPath, including its operations and prospects. Past performance is not necessarily indicative of future results. In addition, AmeriPath's actual results could differ materially from the results anticipated in these forward-looking statements as a result of uncertainties, including risks relating to demand, pricing, government regulation, payments and reimbursements, dependence upon contracts and pathologists, acquisitions, integration of acquired practices, the market for pathology services, competition, and other factors identified in AmeriPath's filings with the Securities and Exchange Commission.